newsfilter
← Latest News
Business Wire·

Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients

– Dosing to Commence Mid-February – – Topline data expected Mid-Year – Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing